Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Honore

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Open Forum Infectious Diseases|September 29, 2025
Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension StudyGeorge R Thompson, Haihui Huang, Sizhou Feng, et al.
Critical Care Medicine|February 10, 2021
Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With InfectionJohn A Kellum, Antonio Artigas, Kyle J Gunnerson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2020
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE TrialGeorge R Thompson, Alex Soriano, Athanasios Skoutelis, et al.
Toxics|June 25, 2025
Nephrotoxicity and Modern Volatile Anesthetics: A Narrative ReviewBenedicte Hauquiert, Aurelien Gonze, Thibault Gennart, et al.
Lancet (London, England)|November 28, 2022
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trialGeorge R Thompson, Alex Soriano, Oliver A Cornely, et al.
Critical Care (London, England)|October 11, 2016
Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applicationsGianluca Villa, Mauro Neri, Rinaldo Bellomo, et al.
Journal of Translational Internal Medicine|February 4, 2020
Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE TrialDominique Breilh, Patrick M Honore, David De Bels, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2024
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE StudyAlex Soriano, Patrick M Honore, Oliver A Cornely, et al.
Journal of Thoracic Disease|March 10, 2017
Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002Zhongheng Zhang, Yucai Hong, Nathan J Smischney, et al.
The Lancet. Infectious Diseases|November 26, 2023
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trialsGeorge R Thompson, Alex Soriano, Patrick M Honore, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Open Forum Infectious Diseases|September 29, 2025
Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension StudyGeorge R Thompson, Haihui Huang, Sizhou Feng, et al.
Critical Care Medicine|February 10, 2021
Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With InfectionJohn A Kellum, Antonio Artigas, Kyle J Gunnerson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2020
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE TrialGeorge R Thompson, Alex Soriano, Athanasios Skoutelis, et al.
Toxics|June 25, 2025
Nephrotoxicity and Modern Volatile Anesthetics: A Narrative ReviewBenedicte Hauquiert, Aurelien Gonze, Thibault Gennart, et al.
Lancet (London, England)|November 28, 2022
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trialGeorge R Thompson, Alex Soriano, Oliver A Cornely, et al.
Critical Care (London, England)|October 11, 2016
Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applicationsGianluca Villa, Mauro Neri, Rinaldo Bellomo, et al.
Journal of Translational Internal Medicine|February 4, 2020
Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE TrialDominique Breilh, Patrick M Honore, David De Bels, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2024
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE StudyAlex Soriano, Patrick M Honore, Oliver A Cornely, et al.
Journal of Thoracic Disease|March 10, 2017
Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002Zhongheng Zhang, Yucai Hong, Nathan J Smischney, et al.
The Lancet. Infectious Diseases|November 26, 2023
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trialsGeorge R Thompson, Alex Soriano, Patrick M Honore, et al.
Pageof 7